KR960705825A - 6-Oxo-nucleosides useful as immunosuppressants - Google Patents

6-Oxo-nucleosides useful as immunosuppressants

Info

Publication number
KR960705825A
KR960705825A KR1019960702453A KR19960702453A KR960705825A KR 960705825 A KR960705825 A KR 960705825A KR 1019960702453 A KR1019960702453 A KR 1019960702453A KR 19960702453 A KR19960702453 A KR 19960702453A KR 960705825 A KR960705825 A KR 960705825A
Authority
KR
South Korea
Prior art keywords
compound
hydrogen
guanosine
trans
formula
Prior art date
Application number
KR1019960702453A
Other languages
Korean (ko)
Inventor
알. 보르쉐르뎅 데이비드
케이. 에드워즈 3세 칼
엘. 마골린 알렉세이
할라지 세르게
에장스피예 안네
Original Assignee
게리 디. 스트리트
메렐 파마슈티칼즈 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 게리 디. 스트리트, 메렐 파마슈티칼즈 인코포레이티드 filed Critical 게리 디. 스트리트
Publication of KR960705825A publication Critical patent/KR960705825A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

본 발명은 면역억제제로서 유용한 신규의 6-옥소-뉴클레오시드 및 이의 제조방법에 관한 것이다.The present invention relates to novel 6-oxo-nucleosides useful as immunosuppressive agents and methods for their preparation.

Description

면역억제제로서 유용한 6-옥소-뉴클레오시드(6-Oxo-nucleosides useful as immunosuppressants)6-Oxo-nucleosides useful as immunosuppressants

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (28)

하기 일반식(I)의 화합물 또는 약학적으로 허용되는 이의 염.A compound of formula (I) or a pharmaceutically acceptable salt thereof. 상기 식에서, X는 OH, N3,NH2, NHR, N(R)2, CN, CH2NH2, CONH2,CO2H, CH2OH, SH 또는 SR이고, R은 C1-C4알킬 또는 수소이며, Z는 수소 또는 NH2이고, n은 1 또는 2이다.Wherein X is OH, N 3 , NH 2 , NHR, N (R) 2 , CN, CH 2 NH 2 , CONH 2 , CO 2 H, CH 2 OH, SH or SR, R is C 1 -C 4 alkyl or hydrogen, Z is hydrogen or NH 2 and n is 1 or 2. 하기 일반식(Ⅱ)의 화합물 또는 약제학적으로 허용되는 이의 염.A compound of formula (II) or a pharmaceutically acceptable salt thereof. 상기 식에서, X1및 X2는 각각 독립적으로 수소 또는 OH이다.Wherein X 1 and X 2 are each independently hydrogen or OH. 제1항에 있어서, n이 1인 화합물.The compound of claim 1, wherein n is 1. 제3항에 있어서, Z가 수소인 화합물.The compound of claim 3, wherein Z is hydrogen. 제4항에 있어서, X가 N3인 화합물.The compound of claim 4, wherein X is N 3 . 제1항에 있어서, (1R,3R)-(트랜스)-1-(6-하이드록시-푸린-9-일)-3-아지도사이클로펜탄인 화합물.The compound of claim 1, which is (1R, 3R)-(trans) -1- (6-hydroxy-purin-9-yl) -3-azidocyclopentane. 제1항에 있어서, (1R,3R)-(트랜스)-9-(3-하이드록시사이클로펜틸)구아노신인 화합물.The compound of claim 1, which is (1R, 3R)-(trans) -9- (3-hydroxycyclopentyl) guanosine. 제1항에 있어서, (±)-(트랜스)-9-(3-하이드록시사이클로펜틸)구아노신인 화합물.The compound of claim 1, which is (±)-(trans) -9- (3-hydroxycyclopentyl) guanosine. 제1항에 있어서, (±)-(시스)-9-(3-하이드록시사이클로펜틸)구아노신인 화합물.The compound of claim 1, which is (±)-(cis) -9- (3-hydroxycyclopentyl) guanosine. 제1항에 있어서, (±)-(시스)-9-(3-하이드록시사이클로헥실)구아노신인 화합물.The compound of claim 1, which is (±)-(cis) -9- (3-hydroxycyclohexyl) guanosine. 제1항에 있어서, (±)-(트랜스)-9-(3-하이드록시사이클로헥실)구아노신인 화합물.The compound of claim 1, which is (±)-(trans) -9- (3-hydroxycyclohexyl) guanosine. 제2항에 있어서, (±)-(트랜스)-9-〔3-하이드록시사이클로펜틸)메틸〕구아노신인 화합물.The compound according to claim 2, which is (±)-(trans) -9- [3-hydroxycyclopentyl) methyl] guanosine. 제2항에 있어서, (±)-(시스,트랜스)-9-〔3,4-디하이드록시사이클로펜틸)메틸〕구아노신인 화합물.The compound of claim 2, which is (±)-(cis, trans) -9- [3,4-dihydroxycyclopentyl) methyl] guanosine. 제2항에 있어서, (±)-(트랜스,트랜스)-9-〔3,4-디하이드록시사이클로펜틸)메틸〕구아노신인 화합물.The compound according to claim 2, which is (±)-(trans, trans) -9- [3,4-dihydroxycyclopentyl) methyl] guanosine. 하기 일반식(Ⅳ)의 화합물을 적절한 AMP 데아미나제와 반응시킴을 포함하는, 하기 일반식(Ⅲ)의 화합물의 제조방법.A process for preparing a compound of formula (III) comprising reacting a compound of formula (IV) with an appropriate AMP deaminase. 상기 식에서, X는 OH, N3, NH2, NHR, N(R)2, CN, CH2NH2, CONH2, CO2H, CH2OH, SH 또는 SR이고, R은 C1-C4알킬 또는 수소이며, Z는 수소 또는 NH2이고, Q는 NH2, 할로겐 또는 OR1이며, R1은 C1-C4알킬이다.Wherein X is OH, N 3 , NH 2 , NHR, N (R) 2 , CN, CH 2 NH 2 , CONH 2 , CO 2 H, CH 2 OH, SH or SR, R is C 1 -C 4 is alkyl or hydrogen, Z is hydrogen or NH 2 , Q is NH 2 , halogen or OR 1 , and R 1 is C 1 -C 4 alkyl. 제15항에 있어서, Z가 수소인 방법.The method of claim 15, wherein Z is hydrogen. 제16항에 있어서, X가 N3인 방법.The method of claim 16, wherein X is N 3 . 면역 억제를 필요로 하는 환자에게 일반식(1) 또는 일반식(2)으로부터 선택된 화합물 또는 약제학적으로 허용되는 이들의 염을 면역 억제 유효량으로 투여함을 포함하는 당해 환자의 면역억제 방법.A method for immunosuppression of a patient comprising administering to a patient in need of immunosuppression a compound selected from Formula (1) or Formula (2) or a pharmaceutically acceptable salt thereof in an immunosuppressive effective amount. 상기 식에서, X는 OH, N3, NH2, NHR, N(R)2, CN, CH2NH2, CONH2, CO2H, CH2OH, SH 또는 SR이고, R은 C1-C4알킬 또는 수소이며, Z는 수소 또는 NH2이고, n은 1 또는 2이며, X1및 X2는 각각 독립적으로 수소 또는 OH이다.Wherein X is OH, N 3 , NH 2 , NHR, N (R) 2 , CN, CH 2 NH 2 , CONH 2 , CO 2 H, CH 2 OH, SH or SR, R is C 1 -C 4 is alkyl or hydrogen, Z is hydrogen or NH 2 , n is 1 or 2, and X 1 and X 2 are each independently hydrogen or OH. 적응성 면역 억제를 필요로 하는 환자에게 일반식(1) 또는 일반식(2)으부터 선택된 화합물 또는 약제학적으로 허용되는 이의 염을 면역 억제 유효량으로 투여함을 포함하는, 당해 환자의 적용성 면역 억제 방법.Applicable immunosuppression in a patient in need thereof, comprising administering to the patient in need of adaptive immunosuppression a compound selected from formula (1) or formula (2) or a pharmaceutically acceptable salt thereof in an immunosuppressive effective amount Way. 상기 식에서, X는 OH, N3, NH2, NHR, N(R)2, CN, CH2NH2, CONH2, CO2H, CH2OH, SH 또는 SR이고, R은 C1-C4알킬 또는 수소이며, Z는 수소 또는 NH2이고, n은 1 또는 2이며, X1및 X2는 각각 독립적으로 수소 또는 OH이다.Wherein X is OH, N 3 , NH 2 , NHR, N (R) 2 , CN, CH 2 NH 2 , CONH 2 , CO 2 H, CH 2 OH, SH or SR, R is C 1 -C 4 is alkyl or hydrogen, Z is hydrogen or NH 2 , n is 1 or 2, and X 1 and X 2 are each independently hydrogen or OH. 제19항에 있어서, 화합물이 (1R,3R)-(트랜스)-9-(3-하이드록시사이클로펜틸)구아노신인 방법.The method of claim 19, wherein the compound is (1R, 3R)-(trans) -9- (3-hydroxycyclopentyl) guanosine. 제19항에 있어서, 환자가 동종이식편 거부 반응에 대한 치료를 필요로 하는 방법.The method of claim 19, wherein the patient requires treatment for allograft rejection. 제19항에 있어서, 환자가 자가면역 질환에 대한 치료를 필요로 하는 방법.The method of claim 19, wherein the patient requires treatment for autoimmune disease. 제22항에 있어서, 자가면역 질환이 인슐린 의존성 당뇨병인 방법.The method of claim 22, wherein the autoimmune disease is insulin dependent diabetes. 제22항에 있어서, 자가면역 질환이 다발성 경화증인 방법.The method of claim 22, wherein the autoimmune disease is multiple sclerosis. 제22항에 있어서, 자가면역 질환이 류마티스성 관절염인 방법.The method of claim 22, wherein the autoimmune disease is rheumatoid arthritis. 제22항에 있어서, 자가면역 질환이 근무력증(myesthenia gravis)인 방법.The method of claim 22, wherein the autoimmune disease is myesthenia gravis. 제22항에 있어서, 자가면역 질환이 전신 루프스 홍반인 방법.The method of claim 22, wherein the autoimmune disease is systemic lupus erythema. 제22항에 있어서, 자가면역 질환이 패혈증성 쇽 증후군인 방법.The method of claim 22, wherein the autoimmune disease is sepsis shock syndrome. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019960702453A 1993-11-12 1994-10-13 6-Oxo-nucleosides useful as immunosuppressants KR960705825A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15108893A 1993-11-12 1993-11-12
US08/151,088 1993-11-12
PCT/US1994/011778 WO1995013277A1 (en) 1993-11-12 1994-10-13 6-oxo-nucleosides useful as immunosuppressants

Publications (1)

Publication Number Publication Date
KR960705825A true KR960705825A (en) 1996-11-08

Family

ID=22537266

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960702453A KR960705825A (en) 1993-11-12 1994-10-13 6-Oxo-nucleosides useful as immunosuppressants

Country Status (12)

Country Link
EP (1) EP0728134A1 (en)
JP (1) JPH09509397A (en)
KR (1) KR960705825A (en)
CN (1) CN1137274A (en)
AU (1) AU677732B2 (en)
CA (1) CA2175897A1 (en)
FI (1) FI962010A (en)
HU (1) HUT74989A (en)
IL (1) IL111544A0 (en)
NO (1) NO961901L (en)
WO (1) WO1995013277A1 (en)
ZA (1) ZA948591B (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU717160B2 (en) * 1994-06-22 2000-03-16 Shire Canada Inc. Novel substituted purinyl derivatives with immunomodulating activity
US5994361A (en) * 1994-06-22 1999-11-30 Biochem Pharma Substituted purinyl derivatives with immunomodulating activity
US6859652B2 (en) 2000-08-02 2005-02-22 Mobile Satellite Ventures, Lp Integrated or autonomous system and method of satellite-terrestrial frequency reuse using signal attenuation and/or blockage, dynamic assignment of frequencies and/or hysteresis
US20110104186A1 (en) 2004-06-24 2011-05-05 Nicholas Valiante Small molecule immunopotentiators and assays for their detection

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN164556B (en) * 1986-03-06 1989-04-08 Takeda Chemical Industries Ltd
IT1229531B (en) * 1988-01-20 1991-09-04 Univ Minnesota DIDEOXIDE / HYDROCARBOCYCLIC NUCLEOSID COMPOUNDS AND PHARMACEUTICAL FORMULATION CONTAINING THEM
AU647822B2 (en) * 1990-09-14 1994-03-31 Marion Merrell Dow Inc. Novel carbocyclic adenosine analogs useful as immunosuppressants

Also Published As

Publication number Publication date
FI962010A (en) 1996-07-10
HU9601262D0 (en) 1996-07-29
WO1995013277A1 (en) 1995-05-18
NO961901L (en) 1996-07-11
AU8120794A (en) 1995-05-29
ZA948591B (en) 1995-06-23
NO961901D0 (en) 1996-05-10
CN1137274A (en) 1996-12-04
HUT74989A (en) 1997-03-28
IL111544A0 (en) 1995-01-24
CA2175897A1 (en) 1995-05-18
FI962010A0 (en) 1996-05-10
AU677732B2 (en) 1997-05-01
EP0728134A1 (en) 1996-08-28
JPH09509397A (en) 1997-09-22

Similar Documents

Publication Publication Date Title
KR940019711A (en) Macrocyclic immunomodulators
CA2298572A1 (en) Deuterated cyclosporine analogs and their use as immunomodulating agents
CA2152486A1 (en) Anticonvulsant sorbopyranose sulfamates
WO1996013512B1 (en) L-ribofuranosyl nucleosides
OA08182A (en) New peptide derivatives with a nitrogenous polycyclic structure, their method of preparation and the pharmaceutical compositions which contain them.
RU93004787A (en) CYCLIC PEPTIDES, METHOD OF THEIR PRODUCTION, PHARMACEUTICAL COMPOSITION ON THEIR BASIS
KR920006357A (en) Carbocyclic adenosine homologues useful as immunosuppressants
CA2122270A1 (en) Tri-substituted tetrahydrofuran antifungals
CA2126337A1 (en) 2-amino-1,3-propanediol compound and immunosuppressant
HU9600298D0 (en) C 22-ring stabilized rapamycin derivatives
IL133891A (en) Valproenoic acid amide derivatives and pharmaceutical compositions containing them
ZA914969B (en) 4-aminobutyric acid compounds,process for the preparation thereof and pharmaceutical preparations containing them
EP1815859A3 (en) Halimide, a cytotoxic marine natural product, and derivatives thereof
KR960705825A (en) 6-Oxo-nucleosides useful as immunosuppressants
RU96115166A (en) ANTI-TRADING SULFAMATS OF PSEVDOFRUCTOPIRANOSE
OA08715A (en) New peptide derivatives with a nitrogenous polyclic structure, their preparation process and the pharmaceutical compositions which contain them.
SG47947A1 (en) Biologically active amines
HU903690D0 (en) Process for the production of medical preparations containing heteroaryl-3-oxo-propionitrile derivatives, for treating arthritis and other autoimmune deseases
KR920005985A (en) Carbocyclic nucleoside analogs useful as immunosuppressants
KR960703122A (en) Novel carbocyclic nucleoside agents useful as selective inhibitors of proinflammatory cytokines
CA2111955A1 (en) Novel tetracyclic compound
OA08881A (en) New tripeptides with a nitrogenous polycyclic structure, their preparation process and pharmaceutical compositions which contain them.
KR920003976A (en) 5'-amine substituted adenosine homologues as immunosuppressive agents
EP0255366A3 (en) Nitrogen- and sulfur-containing lipid compound, their production and use
CA2048347A1 (en) Process for the preparation of deoxynucleosides

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid